Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 5, 2025Hematology

Management of autoimmune hemolytic anemia

View Full Paper
Ask AI
Bookmark
Share

Authors

BFBruno Fattizzo

Discussion

Loading...

Member takes

Overview

Observational analysis on the management of autoimmune hemolytic anemia with immunoglobulin therapies suggests effective treatments like Rituximab.

Key Points

  • Rituximab is preferred for treating relapsed autoimmune hemolytic anemia, showing high effectiveness against traditional methods.
  • Management strategies often include intravenous immunoglobulin and steroids, especially for significant anemia cases.
  • Cold agglutinin disease is discussed separately from autoimmune hemolytic anemia, highlighting treatment distinctions.
  • Novel drug therapies are being developed for managing refractory autoimmune hemolytic anemia, indicating ongoing research trends.

Cite This Study

Bruno Fattizzo (2025) studied this question.

synapsesocial.com/papers/6940224e2d562116f28fc169https://doi.org/10.1182/hematology.2025000719
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1[Treatment strategies for autoimmune hemolytic anemia].2025
  2. 2Autoimmune hemolytic anemia in the era of immunotherapy: from pathogenesis to therapeutic strategies2026
  3. 3[Future directions in the management of warm autoimmune hemolytic anemia].2025
  4. 4Challenges in the diagnosis and management of autoimmune hemolytic anemia: A case-based approach. Experience from a tertiary care hospital in the Haryana region2024
  5. 5Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management2024 · 59 citations